Posted by Michael Wonder on 09 May 2023
Vedanta Biosciences receives fast track designation for VE303
8 May 2023 - VE303 receives fast track designation for prevention of recurrent C. difficile infection ahead of global pivotal Phase 3 study.
Vedanta Biosciences today announced that the US FDA granted fast track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection.
